Safety, pharmacokinetics, and preliminary assessment of efficacy of measermin (recombinant human IGF-1) for the treatment of Rett syndrome

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13548951

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome


*Department of Neurology, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115; ‡Neurosciences Translational Medicine, Pharma Research and Early Development, F. Hoffmann-La Roche AG, 4070 Basel, Switzerland; §Division of Neurology, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027; ¶Department of Anesthesia, Perioperative and Pain Medicine, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115; ¶¶Divisions of Emergency Medicine and Clinical Pharmacology and Toxicology, Hospital for Sick Children, University of Toronto, ON, Canada M5G 1X8. †Division of Emergency Medicine, Boston Children’s Hospital, Boston, MA 02115; ‡Division of Developmental Medicine, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115; ¥Division of Genetics and Genomics, and The Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, MA 02115; ¥¥Department of Pediatrics, Harvard Medical School, Boston, MA 02115; ¥¥¥Division of Respiratory Diseases, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115; ⚫Clinical Research Center, Boston Children’s Hospital, Boston, MA 02115; ‡‡Department of Cardiology, Boston Children’s Hospital, Boston, MA 02115; ‡§Department of Obstetrics, Gynecology and Reproductive Biology, Laboratory of Genital Tract Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215; and ‡¨Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139

Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder mainly affecting females and is associated with mutations in MECP2, the gene encoding methyl CpG-binding protein 2. Mouse models suggest that recombinant human insulin-like growth factor 1 (IGF-1) (rhIGF1) (mecasermin) may improve many clinical features. We evaluated the safety, tolerability, and pharmacokinetic profiles of IGF-1 in 12 girls with MECP2 mutations (9 with RTT). In addition, we performed a preliminary assessment of efficacy using automated cardiorespiratory measures, EEG, a set of RTT-oriented clinical assessments, and two standardized behavioral questionnaires. This phase 1 trial included a 4-week multiple ascending dose (MAD) (40–120 µg/kg twice daily) period and a 20-week open-label extension (OLE) at the maximum dose. Twelve subjects completed the MAD and 10 the entire study, without evidence of hypoglycemia or serious adverse events. Mecasermin reached the CNS compartment as evidenced by the increase in cerebrospinal fluid IGF-1 levels at the end of the MAD. The drug followed nonlinear kinetics, with greater distribution in the peripheral compartment. Cardiorespiratory measures showed that apnea improved during the OLE. Some neurobehavioral parameters, specifically measures of anxiety and mood also improved during the OLE. These improvements in mood and anxiety scores were supported by reversal of right frontal alpha band asymmetry on EEG, an index of anxiety and depression. Our data indicate that IGF-1 is safe and well tolerated in girls with RTT and, as demonstrated in preclinical studies, ameliorates certain breathing and behavioral abnormalities.

Initial drug trials for RTT, including two randomized placebo-controlled trials, were based on neurobiological aspects of the disorder derived from pathological and laboratory studies of affected individuals (4, 5). The identification of MECP2 mutations, which cause a defect in synaptic maturation and maintenance (6), as the etiology of most cases of RTT, represented a major breakthrough for the development of new treatments. The creation of experimental models of the disorder led to the identification of downstream therapeutic strategies (4). Substantial reversal of mouse model neurologic phenotypes by genetic manipulations, at different developmental stages (7, 8), has supported the testing of several candidate drugs (4, 9). A particularly attractive candidate drug is recombinant human insulin-like growth factor 1 (rhIGF-1) (IGF-1). IGF-1 is one of the most potent activators of the AKT signaling pathway and may potentiate the function of brain-derived neurotrophic factor, a key target of MeCP2’s transcriptional regulation (10). There is also evidence that MeCP2 regulates the expression of IGF-binding protein 3

Significance

This paper provides unique insights into mechanism-based therapeutics for Rett syndrome (RTT), a devastating neurodevelopmental disorder. This clinical trial was based on pioneer preclinical work from the laboratory of M.S. Outcome measures include clinical instruments, standardized behavioral measures, and biomarkers, the latter being not only objective but also applicable to experimental studies. We believe this work will have a major impact on the understanding and treatment of RTT, as well as other neurodevelopmental disorders.


The authors declare no conflict of interest.

1This Direct Submission article had a prearranged editor.

2Deceased March 10, 2009.

3To whom correspondence should be addressed. E-mail: walter.kaufmann@childrens.harvard.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1311141111/-/DCSupplemental.
(IGFBP3), a major IGF-1-binding factor that is increased in brains of RTT patients and Mecp2-null mice (11). Furthermore, administration of IGF-1 restores dendritic spine dynamics in Mecp2-deficient mice (12). The most compelling data supporting IGF-1 as a treatment for RTT come from two studies demonstrating that systemic administration of either full length IGF-1 or its active peptide fragment reverses, at least partially, many RTT-relevant features in Mecp2-deficient mice (13, 14). Among the latter are locomotor function impairment, breathing abnormalities, and heart rate irregularities. These improvements seem to reflect IGF-1’s effect on defective synaptic maturation and maintenance secondary to Mecp2 deficit (14).

Mecasermin, recombinant human IGF-1, is already Food and Drug Administration-approved for the long-term treatment of growth failure in children with severe primary IGF-I deficiency (Laron syndrome) (15). We carried out a multiple ascending dose (MAD) study followed by an open-label extension (OLE) period with mecamerin in a group of 12 girls with MECP2 mutations, 9 of whom had RTT. Here, we report our findings on safety, tolerability, pharmacokinetics (PK), and preliminary assessments of efficacy. The latter include evaluations of neurobehavioral measures, exploratory biomarkers, and their corresponding pharmacodynamics (PD) data.

Results

Twelve girls with MECP2 mutations participated in the 4-wk MAD; 10 of them continued and completed the subsequent 20-wk OLE. Fig. S1 illustrates the timeline of this phase 1 trial. Participants’ demographic and baseline characteristics are shown in Table 1. Nine subjects met full diagnostic criteria for RTT and all continued in the OLE. The 4-wk MAD focused on obtaining PK data, determining cerebrospinal fluid (CSF) penetration, initial evaluations of safety and tolerability, and estimating feasibility of automated cardiorespiratory measures as biomarkers for treatment response. The OLE was designed to obtain additional information on safety, tolerability, and the aforementioned cardiorespiratory measures after chronic dosing, as well as preliminary data on neurologic and behavioral parameters of clinical relevance to RTT. These neurobehavioural evaluations were based on questionnaires and assessments used in an ongoing multisite longitudinal study [the Rett Natural History study (U54 HD061222)] and on two standardized measures of problem behaviors. Data on safety, tolerability, and PK is reported for all 12 MECP2 mutation-positive subjects, whereas preliminary efficacy and PD data only for the 9 subjects with RTT. During the MAD, mecamerin dosing was escalated over a 4-wk period, beginning with twice daily (BID) injections of 40 μg/kg the first week, 80 μg/kg the second week, and 120 μg/kg during the third and fourth weeks, as depicted in Fig. S2. CSF samples were obtained before drug administration and after completing the fourth week (Fig. S2). Fig. 1 illustrates levels of IGF-1 and IGFBP3, the main IGF-1-binding protein (10, 11), in serum and CSF. There was a significant increase in IGF-1 but not IGFBP3 in both compartments at the end of the MAD. At the start of the OLE, subjects went through an identical dose escalation, staying on the maximum dose of 120 μg/kg for the remaining 17 wk of treatment.

Serum IGF-1 concentrations were first analyzed by a non-compartmental analysis (16) comparing different doses. A log-linear terminal phase was observed for 4-6 h postdosing (Fig. S4). The slopes of this decay allowed the estimation of terminal elimination half-lives (t_{1/2,T}) and mean residence times in the body (MRT_{b}) as shown in Table S1. Maximal concentrations (C_{max}) and the times to reach them (t_{max}) were also documented. The areas under the curve (AUC; t, time of last observation) up to the last observation lacked dose proportionality, suggesting nonlinear kinetics (Fig. 2B). The starting dose of 40 μg/kg elicited a mean AUC = 2,050 ng·h/mL, while the area for twice that dose increased by just 75%. When the starting dose was tripled, the increment was nearly the same. Nonlinearity is also supported by the early parts of the concentrations profiles, with upward deviations after reaching maximum levels. We also carried out a compartmental analysis using a two-compartment model based on calculated Akaike and Bayesian information criteria, as well as on the residuals analysis (16). A Michaelis-Menten elimination kinetics (16) with first order absorption and a distribution clearance parameterization provided the best goodness of fit, compared with first order or mixed elimination alternatives. The volume of distribution for the central compartment (V_1/f) was estimated to be 7.71 ± 0.78 L (mean ± SE) and for the peripheral compartment it was 33.5 ± 16 L. The other parameters in the model were estimated for intercompartmental clearance as 0.58 ± 0.045 L/h, for the maximum elimination rate as 1.02 ± 0.4 μg·kg^{-1}·h^{-1}, and for the Michaelis-Menten constant (C_{max}) as 4.62 ± 3.7 ng/mL. Individual subjects’ noncompartmental curves are depicted in Fig. S3 and Fig. S4 demonstrates the appropriateness of the proposed models (i.e., predicted vs. observed grouped data).

Based on direct compliance monitoring and serum levels, s.c. injections were well tolerated and no incidences of hypoglycemia or errors in dose administration were detected. During the MAD, one serious adverse event occurred (respiratory distress) and was determined to be unrelated to the study drug (10, 15). During the MAD, only two adverse events (nausea and vomiting) were considered as probably related to the study drug and preceded withdrawal from the OLE. A similar profile of safety and

Table 1. Subject demographics and characteristics at baseline

<table>
<thead>
<tr>
<th>Age, y</th>
<th>Diagnosis</th>
<th>Stage</th>
<th>MECP2 mutation</th>
<th>Concomitant medications</th>
<th>Breathing phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Classic</td>
<td>II</td>
<td>R168X</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>MRD*</td>
<td>n/a²</td>
<td>C1135_1142 del</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>MRD*</td>
<td>n/a²</td>
<td>C1135_1142 del</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>Classic</td>
<td>II</td>
<td>C790_808 del</td>
<td>Levetiracetam</td>
<td>BH, HV, AE</td>
</tr>
<tr>
<td>5</td>
<td>Classic</td>
<td>III</td>
<td>Large de exon 3 and 4</td>
<td>None</td>
<td>BH, HV</td>
</tr>
<tr>
<td>4</td>
<td>Classic</td>
<td>III</td>
<td>C1159_1273 del</td>
<td>None</td>
<td>AE²</td>
</tr>
<tr>
<td>8</td>
<td>Classic</td>
<td>III</td>
<td>R255X</td>
<td>Lamotrigine, lorazepam, melatoninin</td>
<td>BH, AE³</td>
</tr>
<tr>
<td>4</td>
<td>Classic</td>
<td>III</td>
<td>R255X</td>
<td>None</td>
<td>AE</td>
</tr>
<tr>
<td>8</td>
<td>Classic</td>
<td>III</td>
<td>T158M</td>
<td>None</td>
<td>BH, AE³</td>
</tr>
<tr>
<td>3</td>
<td>MRD</td>
<td>n/a²</td>
<td>R306C</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>10</td>
<td>Classic</td>
<td>III</td>
<td>Large de exon 1 and 2</td>
<td>Gabapentin, diastat</td>
<td>BH, AE, cyanosis⁵</td>
</tr>
<tr>
<td>8</td>
<td>Classic</td>
<td>III</td>
<td>P322L</td>
<td>Levetiracetam</td>
<td>BH, AE, cyanosis⁵</td>
</tr>
</tbody>
</table>

AE, air expulsion; BH, breath holding; HV, hyperventilation.

*Subjects did not continue in OLE.

³Staging not applicable (n/a) to non-RTT.

²Subject with mild apnea (apneic episodes >10 s and <5 apneas per hour).

³Subjects with moderate-severe apnea (apneic episodes >10 s and >5 apneas per hour).
tolerability, with no unexpected, progressive, or related serious adverse events, was observed during the OLE. Although a high proportion of the subjects had abnormal cholesterol levels at baseline, these did not worsen during the trial. For details on adverse events, see Table S2.

Using cardiorespiratory data obtained with a BioRadio device (17), we calculated the apnea (18) and hyperventilation (19) indices and compared the start and end of the MAD (pre- to post-MAD), start and end of the OLE (pre- to post-OLE), and beginning and end of the entire trial (pre-MAD to post-OLE). We applied paired t tests, Wilcoxon signed rank tests, and a random intercept (RI) model, illustrating time effects at each time point (post-MAD, pre-OLE, and post-OLE compared with pre-MAD). As illustrated in Table 2 (see “apnea index by time point” entries), based on the RI model which accounts for within-subjects correlation, the improvement in the apnea index was significant at the end of the OLE in comparison with start of the MAD. Improvements in the apnea index were comparable when only the five subjects with clinically significant apnea (apnea episodes >10 s), four of whom had moderate–severe apnea, were included in the analyses (Table S3). Fig. S5 depicts the trajectories of the apnea index for all subjects. In addition, despite the small sample, we tested the effect of age as a covariate in the RI model for all nine subjects with RTT. The effect of age and its interaction with the respective time points was positive and significant, namely the improvements in the apnea index were more significant in older subjects. These patterns of improvement were not observed for the hyperventilation index (see “hyperventilation index by time point” entries in Table 2).

The specificity of the apnea index improvements are underscored when other respiratory parameters (20), typically not used in the clinical context, are examined. Table S4 shows that during the OLE, for instance, the percent epoch in slow respiratory rate and the mean total respiratory cycle times (Ttot) in slow respiration also decreased significantly but not the percent epoch in rapid respiratory rate and the mean Ttot in rapid respiration. Similar results were found in the MAD. There were also changes in the cardiac parameters, namely a reduction in the percent epoch in normal heart rate with a concurrent increase in the percent epoch in rapid heart rate when the beginning and end of the OLE were compared. Variance in heart rate also decreased, although not significantly (Table S4). Similar to the breathing parameters, changes in cardiac variables demonstrated the same trend during the shorter MAD and the longer OLE. Preliminary PD analysis also detected a positive response, namely a decrease in the apnea index, over the course of treatment. Just in a few cases this decrease leveled off or, in one case, seemed to revert at the end of the MAD (Fig. S6 illustrates examples of different PD profiles).

During the OLE, preliminary efficacy data were gathered by administering two RTT-oriented clinician assessments and two standardized behavioral measures to the nine RTT subjects. We focused on established instruments already reported in the literature (21–25), and did not include parent or clinician global impression assessments, to decrease data subjectivity and allow for future comparisons with other publications. Neurologic and behavioral parameters were measured by two evaluations, in line with the Rett Syndrome Behavioral Questionnaire (RSBQ) (22, 23) and the Anxiety Depression and Mood Scale (ADAMS) (24, 25). We performed exploratory comparisons between onset and end of the OLE using t tests and the Wilcoxon signed rank test. Although not significantly different, total scores showed a trend toward improvement in all instruments. We then organized the subscales of these measures into neurobehavioral domains (e.g., motor, breathing/autonomic, problem behavior) and subjected them to exploratory t tests comparing the MAD to the OLE. We followed these hierarchical analyses by examining the items in the same subscales. These analyses revealed significant or trend-level changes in the breathing/autonomic and behavioral domains. However, the direction of change in breathing and peripheral autonomic subscales were inconsistent. For instance, breath-holding items in the RSBQ showed improvement whereas those on the clinical assessment (CA) and motor–behavioral assessment (MBA) worsened. Similar inconsistencies were present for peripheral autonomic scales/items. Subscales and items representing alertness, activity, anxious behaviors, or abnormal mood demonstrated consistent improvements, whereas those recording irritability, aggressiveness, disruptive/hyperactive behavior, communication, and motor domains did not (Table 3 and Fig. S7).

Relative right-sided resting frontal (alpha band) EEG asymmetry has been used in multiple studies as an index of anxiety and depression (26), including pediatric populations (27). Left (L) greater than right (R) alpha power is typically interpreted as more positive vs. negative (less anxious vs. more anxious) behavior, whereas R > L is viewed as the reverse. As depicted in Fig. 3, six subjects evaluated during the OLE with EEG demonstrated R > L asymmetry (i.e., more anxious). Although the degree of asymmetry was variable, five of the six showed a decrease in the asymmetry index and in three it was reversed. A paired-samples t test revealed that this group trend toward L > R asymmetry (i.e., reduction in anxiety) was significant. Moreover,

**Fig. 1.** IGF-1 and IGFBP-3 levels in CSF and serum pre- and post-MAD. The Mean and SE of IGF-1 and IGFBP-3 in serum and CSF are shown (P values based on Student’s t test). CSF and serum samples were obtained before IGF-1 administration on day 1 and 1–2 h after dose on day 29 (n = 12). Levels of IGF-1 in serum and CSF more than doubled, indicating IGF-1 reaches the CNS compartment. IGFBP3, the main IGF-1-binding protein, did not significantly increase in serum or CSF.

**Fig. 2.** (A) Serum IGF-1 concentrations show a log-linear terminal phase 4–6 h after dosing. Serum IGF-1 concentrations were analyzed by a noncompartmental analysis comparing escalating doses at days 1, 8, 15, and 29. A log-linear terminal phase was observed after 4–6 h postdosing. The slopes of decay allowed the estimation of t1/2μ and MRTμ, described in Table S1. (B) As shown, the mean and SE of the AUC of IGF-1 suggests nonlinear kinetics. The AUC up to the last observation lacked dose proportionality, suggesting nonlinear kinetics. The lowest dose of 40 μg/kg BID dose elicited a mean AUC = 2,050 ng/mL, whereas the area for twice that dose (80 μg/kg BID) increased just about 75%. When the lowest dose was tripled (120 μg/kg BID) at day 15, the increment was nearly the same.
the group reduction in the R > L asymmetry index correlated with improvements in measures of mood abnormalities and, to lesser extent in measures of breathing abnormalities and anxiety (Table S5). Analyses of cardiorespiratory and neurobehavioral parameters excluding the two individuals in Hagberg stage II (i.e., end of regression period) did not yield significantly different results from those including all nine RTT subjects.

Discussion

Our findings indicate that IGF-1 is safe for use in girls with MECP2 mutations, including those meeting diagnostic criteria for RTT. We found that mecasermin reaches the CNS and that its kinetics are complex, as expected from a protein that is cleaved and binds its receptor and interacting proteins (10, 11, 28, 29). Our preliminary efficacy analyses suggest that, when administered over several weeks, mecasermin improved certain aspects of the RTT phenotype, most notably, abnormal behaviors (i.e., anxiety) and breathing abnormalities (i.e., apnea). Changes in breathing abnormalities were better characterized using automated measurements of cardiorespiratory function. The evaluation of potential biomarkers also successfully delineated behavioral abnormalities with right-sided frontal alpha band EEG asymmetry, an index of anxiety and depression, showing a trend toward reversal in most RTT subjects exhibiting the phenomenon. Overall, the findings of this phase 1 trial are in agreement with preclinical data suggesting IGF-1 is a safe and beneficial treatment for RTT (13, 14).

As recently reported by Pini et al. (30), mecasermin administration is relatively safe and well tolerated. In our own phase 1 study, several expected adverse events, such as increased tinnitus size and related snoring, were observed but were relatively mild and nonprogressive and did not lead to withdrawal from the trial. Most subjects had elevated cholesterol; however, this preceded IGF-1 administration and did not worsen with the drug. Therefore, concerns about metabolic syndrome raised by a recent animal study (31) were not supported by our trial. The most common adverse event, early signs of puberty, may be significant as some reports have shown accelerated puberty (i.e., early adrenarche) in RTT (32, 33). Nonetheless, because hormonal levels were within normal ranges throughout the study, this issue deserves further investigation. In summary, at the doses used in this (240 $\mu$g·kg$^{-1}$·d$^{-1}$) and the previously published (200 $\mu$g·kg$^{-1}$·d$^{-1}$) trial (30), mecasermin is a safe treatment.

Our data indicate that mecasermin administration increases IGF-1 levels in the CNS (10); therefore, our data on efficacy and some of the adverse events could be attributed to the presence of IGF-1 in the brain. The IGF-1 increase in CSF depicted in Fig. 1 is consistent with the increase in IGF-1 in the plasma. This supports the hypothesis that IGF-1 is present in the CNS and modulates the level of IGF-1 in the plasma. This finding is in line with the partial correction of bradycardia in the Mecp2-null mouse (14).

Our preliminary efficacy evaluations on neurobehavioral parameters provided a mixed picture. Whereas some measures indicated improvements, others worsened. This was particularly the case for abnormalities in breathing and peripheral autonomic function. A similar inconsistent pattern was found for abnormalities in breathing and peripheral autonomic function. A similar inconsistent pattern was found for abnormalities in breathing and peripheral autonomic function. A similar inconsistent pattern was found for abnormalities in breathing and peripheral autonomic function.

Table 2. Summary of breathing indices for all RTT subjects by time point ($n = 9$)

<table>
<thead>
<tr>
<th>Breathing indices</th>
<th>Pre-MAD</th>
<th>Post-MAD</th>
<th>Pre-OLE</th>
<th>Post-OLE</th>
<th>Pre-MAD to Post-OLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apnea index (mean ± SE)</td>
<td>10.11 ± 19.34</td>
<td>5.11 ± 9.68</td>
<td>4.67 ± 6.81</td>
<td>3.00 ± 5.72</td>
<td>-7.12 ± 4.58</td>
</tr>
<tr>
<td>Student’s t P</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.159</td>
</tr>
<tr>
<td>Wilcoxon signed rank P</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.094</td>
</tr>
<tr>
<td>RI model</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.018</td>
</tr>
<tr>
<td>Hyperventilation index (mean ± SE)</td>
<td>3.55 ± 6.71</td>
<td>3.00 ± 6.59</td>
<td>6.44 ± 16.86</td>
<td>3.66 ± 8.97</td>
<td>0.12 ± 0.93</td>
</tr>
<tr>
<td>Student’s t P</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.908</td>
</tr>
<tr>
<td>Wilcoxon signed rank P</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.675</td>
</tr>
<tr>
<td>RI model</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.963</td>
</tr>
</tbody>
</table>

Hyperventilation index (mean ± SE)
However, behaviors under the categories of anxiety (i.e., including fear and avoidance) and mood abnormalities (e.g., inappropriate laughter) showed modest although consistent improvements among measures that included two standardized behavioral scales (i.e., RSBQ, ADAMS). These findings were supported by the partial or complete reversal of right-sided alpha band frontal EEG asymmetry in five of the six subjects presenting with this phenomenon, which correlated with improved scores on mood abnormalities and anxiety. Because EEG frontal asymmetry has been linked to depression and particularly to anxiety in children (26, 27), its use in RTT and other neurodevelopmental disorders may serve as an effective tool for assessing drug efficacy. Our findings of IGF-1’s effect on anxiety are in agreement with data from studies in the animal model (14).

The data presented here suggest that administration of IGF-1 is a promising treatment for RTT. Its safety and tolerability profiles are acceptable considering the severity of the targeted symptoms. However, the potential long-term use of mecasermin should be weighed against its potential effects on puberty, which is already accelerated in RTT (32, 33). The complex pharmacology of IGF-1 makes the determination of an optimal dosage difficult; the positive effects reported here indicate that long-term treatment may be necessary, which is not surprising considering IGF-1’s likely effects on synaptic maturation and maintenance (6, 13, 14). The effect of IGF-1 was mild and selective, influencing certain cardiorespiratory and neurobehavioral features of RTT. Although this may seem unexpected given the context of IGF-1’s extensive efficacy in the mouse model (14), it is not surprising compared with trial results in other neurodevelopmental disorders. In fragile X syndrome, mGluR5 antagonists (43) and GABA-B agonists (44) had similar selective effects in human trials, but were preceded by mGluR5 antagonists (43) and GABA-B agonists (44) had similar selective effects in human trials, but were preceded by mGluR5 antagonists (43). Nonetheless, the use of automated measures such as the BioRadio for cardiorespiratory function (17) or EEG asymmetry profiles for anxiety and mood (26, 27) strengthened clinician- and parent-reported data and support future exploration of biomarkers. Additional biomarker data—namely the Q sensor (47) for recording motion and hand stereotypes and visual evoked potentials for examining cortical function (48)—was collected as part of this trial and needs to be analyzed and reported in future publications.

### Methods

**Sample.** Characteristics of our cohort are shown in Table 1 and SI Methods. The study was approved by the Institutional Review Board of Boston Children’s Hospital and informed consent was obtained from the parent of each participant. Further information is provided in SI Methods.

**Study Design and Safety Measures.** Unblinded phase 1 study designed to establish PK profile (4-wk MAD) and long-term safety and tolerability (20-wk OLE) of IGF-1 in girls with RTT (Fig. S1). Subjects received twice daily (BID) s.c. injections at 40 μg/kg (week 1), 80 μg/kg (week 2), and 120 μg/kg (weeks 3, 4, OLE) (Fig. S2). Safety was assessed by evaluations listed in Table S6. Detailed information is provided in SI Methods.

**PK and PD Analyses.** Sera were obtained at different daily time points during the MAD, and at each visit during the OLE, while CSF only at the beginning and end of the MAD (Fig. S2). Methodologies for IGF-1 and IGFBP3 measurements, and PK and pharmacodynamics analyses, are detailed in SI Methods.

**Automated Cardiorespiratory Measures.** Time synchronized chest respiratory inductive plethysmography, three lead electrocardiography, and video recordings are detailed in SI Methods.

---

**Table 3. Neurobehavioral measures between V1 and V5**

<table>
<thead>
<tr>
<th>Measure</th>
<th>V1 mean</th>
<th>V5 mean</th>
<th>Mean difference</th>
<th>Mean difference SE</th>
<th>Student’s t P</th>
<th>Wilcoxon signed rank P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Behavioral subtotal (MBA)</td>
<td>24.00</td>
<td>19.88</td>
<td>−4.11</td>
<td>1.11</td>
<td>0.006</td>
<td>0.016</td>
</tr>
<tr>
<td>Passive/unengaged (CA)</td>
<td>0.33</td>
<td>0.00</td>
<td>−0.33</td>
<td>0.17</td>
<td>0.081</td>
<td>0.250</td>
</tr>
<tr>
<td>Intermittent laughter (CA)</td>
<td>0.33</td>
<td>0.00</td>
<td>−0.33</td>
<td>0.17</td>
<td>0.081</td>
<td>0.250</td>
</tr>
<tr>
<td>Fear/anxiety subtotal (RSBQ)</td>
<td>3.55</td>
<td>2.77</td>
<td>−0.79</td>
<td>0.66</td>
<td>0.274</td>
<td>0.281</td>
</tr>
<tr>
<td>Spells of laughter at night (RSBQ)</td>
<td>0.77</td>
<td>0.44</td>
<td>−0.33</td>
<td>0.17</td>
<td>0.081</td>
<td>0.250</td>
</tr>
<tr>
<td>Social avoidance subtotal (ADAMS)</td>
<td>4.55</td>
<td>3.11</td>
<td>−1.44</td>
<td>0.84</td>
<td>0.122</td>
<td>0.109</td>
</tr>
</tbody>
</table>

V1, visit 1 of OLE; V5, visit 5 of OLE.
Neurobehavioral Assessments. Table S4 lists the multiple measures of neurologic and other functions obtained during the OLE. Additional information is presented in SI Methods.

EEG Recordings. EEG recording, spectral power analysis, and frontal asymmetry scores were performed as reported (49–51) and detailed in SI Methods.

Statistical Analyses. Standard descriptive and comparative statistics were employed. Specific tests are specified in Results and SI Methods.